

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 October 2014 (23.10.2014)



(10) International Publication Number
WO 2014/169833 A9

(51) International Patent Classification:

C07J 3/00 (2006.01) *A61K 31/573* (2006.01)
C07J 7/00 (2006.01) *A61K 31/58* (2006.01)
C07J 15/00 (2006.01) *A61P 25/00* (2006.01)
A61K 31/57 (2006.01)

(21) International Application Number:

PCT/CN2014/075594

(22) International Filing Date:

17 April 2014 (17.04.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2013/074323 17 April 2013 (17.04.2013) CN

(71) Applicant: **SAGE THERAPEUTICS, INC.** [US/US];
215 First Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **BOTELLA, Gabriel Martinez**; 17 Parmenter
Road, Wayland, Massachusetts 01778 (US). **HARRISON,
Boyd L.**; 9 Wheatston Court, Princeton Junction, New Jer-
sey 08550 (US). **ROBICHAUD, Albert Jean**; 3 River-
view Court, Ringoes, New Jersey 08551 (US). **SALI-**

TURO, Francesco G.; 25 Baker Drive, Marlborough,
Massachusetts 01752 (US). **BERESIS, Richard Thomas**;
Apartment 2504, Building 1, 199 Shimen #2 Road, Shang-
hai 200040 (CN).


(74) Agent: **LIU, SHEN & ASSOCIATES**; 10th Floor, Build-
ing 1, 10 Caihefang Road, Haidian District, Beijing
100080 (CN).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,

[Continued on next page]

(54) Title: 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF



(I)

(57) Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein, R^1 , R^2 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^5 , R^6 , and R^7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.



UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version:

3 March 2016

(15) Information about Correction:

see Notice of 3 March 2016

Published:

— with international search report (Art. 21(3))